Genetics & Genomics Frontiers — 2026-05-22
This week's genetics and genomics landscape is shaped by fresh regulatory milestones from the FDA, a wave of new companion diagnostic approvals in oncology, and a growing market outlook for genome editing that projects the sector reaching $55.7 billion by 2035. The genomics workforce is also expanding to meet surging clinical demand, with educational institutions ramping up genetics programs. Key FDA actions on liquid biopsy and ctDNA-guided therapy mark a turning point for precision oncology.
Genetics & Genomics Frontiers — 2026-05-22
Key Highlights
FDA Approves MRD-Guided Therapy in Bladder Cancer — A Historic First
In what GenomeWeb is calling a landmark decision, the FDA has approved MRD-guided use of Genentech's Tecentriq in bladder cancer, paired with the Natera Signatera companion diagnostic (CDx). This represents the first FDA approval of a ctDNA MRD-guided therapy and also marks the first agency approval of a blood-based MRD test as a CDx — a significant validation of liquid biopsy technology as a clinical decision-making tool.
Guardant Health Upgraded CDx Clears FDA
Guardant Health's upgraded companion diagnostic has secured FDA approval this week. The blood-based test collects both genomic and epigenomic information to guide treatment decisions in patients with advanced cancer, reflecting how multi-modal liquid biopsy platforms are increasingly entering regulatory approval pathways.
Foundation Medicine Assay Approved as CDx for Tepmetko in Lung Cancer
The FDA has also approved a Foundation Medicine tissue assay as a companion diagnostic for Tepmetko (tepotinib) in MET-altered non-small cell lung cancer. Foundation Medicine had previously received CDx approval for its FoundationOne Liquid CDx alongside EMD Serono's Tepmetko.
Personalis Wins Medicare Coverage for MRD Test in Breast Cancer
Personalis has secured Medicare coverage for its MRD (minimal residual disease) test for breast cancer pre-surgical treatment monitoring — a critical reimbursement milestone that expands patient access to genomic monitoring tools.
Proposed Law Would Modernize CLIA With LDT Oversight Provisions
A newly proposed piece of legislation would update the Clinical Laboratory Improvement Amendments (CLIA) framework with new provisions for laboratory-developed test (LDT) oversight. The bill would provide tools to track performance and validation of LDTs and affirm a 2025 court decision that they are not subject to FDA oversight — potentially reshaping the regulatory landscape for genomic diagnostics.
Genome Editing Market Projected to Hit $55.7 Billion by 2035
A new market analysis published May 21 from Healthcare Foresights projects the global genome editing market will reach USD 55.7 billion by 2035, growing at a 17.4% CAGR.
Genetics Workforce Demand Surges — SCU Expands Programs
Southern California University of Health Sciences (SCU) announced this week that it is preparing students for a growing genetics and genomics workforce, citing demand for professionals who can interpret increasingly complex genetic data as the sector expands across healthcare settings.
Oxford Nanopore Previews RNA, High-Throughput, and Proteomics Products
At its user meeting in London this week, Oxford Nanopore previewed products for RNA analysis, high-throughput sequencing, and proteomics. The UK company also teased long-term R&D goals including a new nanopore design and protein sequencing capabilities.
DNA End Motif Sequences Predictive of Immunotherapy Response in Head-and-Neck Cancer
A study highlighted by GenomeWeb this week found that regional motif diversity scores from circulating DNA provided a more granular view of the genetic changes separating immunotherapy responders from non-responders in head-and-neck cancer patients — opening a potential new biomarker avenue for treatment decisions.
GWAS Meta-Analysis Links Blood Metabolites to Genetic Variants
A large GWAS meta-analysis this week linked blood metabolites to both common and rare genetic variants, adding new granularity to our understanding of how genetic architecture shapes metabolic phenotypes at the population level.
QIAGEN to Integrate NVIDIA Computing and AI Into Bioinformatics Platform
QIAGEN announced plans to integrate NVIDIA computing and AI capabilities into its bioinformatics platform, reflecting the broader convergence of genomics and AI infrastructure at the enterprise level.
Delfi Diagnostics: cfDNA Assay Nearly Triples Lung Cancer Screening Rates
Delfi Diagnostics shared clinical utility data showing that access to its cell-free DNA (cfDNA) liquid biopsy assay nearly tripled lung cancer screening rates, in a demonstration of the test's potential for population-level impact.
Analysis
The most significant development this week is the FDA's approval of MRD-guided Tecentriq therapy using Natera's Signatera ctDNA test in bladder cancer — a double first for the field. By approving both a ctDNA test as a companion diagnostic and the therapy guided by that test's results in a single decision, the FDA has established a critical regulatory precedent. This paves the way for similar MRD-guided approaches across oncology indications, potentially transforming how post-treatment monitoring and therapeutic decision-making intersect.
Coupled with Guardant Health's upgraded multi-modal CDx approval and Foundation Medicine's tissue assay clearance for lung cancer, this week represents one of the most active periods for genomics-driven regulatory action in recent months. The Personalis Medicare coverage decision adds the crucial reimbursement dimension — historically a major barrier to widespread adoption of genomic monitoring tests.
The proposed CLIA legislation updating LDT oversight is also worth watching closely: affirming that LDTs are not FDA-regulated while improving internal performance tracking could accelerate the pace at which new genomic assays reach patients, though it may also renew debates about quality standards.
What to Watch
- CLIA/LDT legislation progress: The proposed bill to update CLIA oversight for laboratory-developed tests will be closely monitored by diagnostic developers and clinical labs.
- Oxford Nanopore product launches: Following previews at its London user meeting, watch for formal launch timelines on new RNA analysis and high-throughput sequencing products, as well as early protein sequencing announcements.
- Pediatric cancer NGS surveillance guidance: A new study suggesting surveillance in pediatric cancer patients with pathogenic variants revealed by NGS is drawing attention — further clinical guidance or policy response may follow.
- Mosaic chromosomal alterations in UK Biobank: Newly mapped mosaic chromosomal alterations in UK Biobank blood samples may yield follow-up studies on aging, cancer risk, and clonal hematopoiesis.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
